Reversing ABCC2-Mediated Oxaliplatin Resistance in Human PANC-1 Cells Using the CRISPR_cas9 System
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a highly aggressive malignancy that often shows minimal symptoms, early signs of the disease are difficult and often impossible to identify until the later stages of the disease due to the location of the pancreas. Oxaliplatin is a critical...
Auckland University of Technology,
|Online Access:||Get fulltext|